長青集團(002616.SZ):子公司創爾特熱能擬以資本公積金轉增註冊資本2.5712億元
格隆匯 10 月 19日丨長青集團(002616.SZ)公佈,為滿足生產經營需要,公司全資子公司創爾特熱能科技(中山)有限公司(“創爾特熱能”)擬以資本公積金轉增註冊資本2.5712億元;增資完成後,創爾特熱能註冊資本將由人民幣6920萬元增加至3.2632億元,創爾特熱能仍為公司的全資子公司。轉增註冊資本後,創爾特熱能資本公積餘額符合《中華人民共和國公司法》的相關要求。
此次增資後,公司仍將通過直接和間接合計持有創爾特熱能100%股權,不影響公司財務報表合併範圍,不會對公司財務及經營狀況產生重大不利影響,不存在損害公司及全體股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.